Jake M Holdreith is a partner in the Minneapolis office of Robins Kaplan LLP and is also admitted to practise in New York. Mr Holdreith leads the firm’s health and life sciences industry group. He creatively resolves conflicts, consistent with the strategic goals of his clients, and tries complex lawsuits involving intellectual property, state and federal regulation, and business disputes. His litigation experience includes disputes in courts in the United States, Europe and Hong Kong. He has obtained multiple jury verdicts for patent owners ranging from $3 million to over $34 million, as well as multiple defence judgments.
Mr Holdreith was trial counsel in Auxilium Pharmaceuticals v Upsher-Smith Laboratories (Hatch-Waxman non-infringement judgment on 10 patents); Purdue Pharmaceutical Products LP v Actavis Elizabeth LLC (Hatch-Waxman patent infringement trial resulting in invalidation of asserted patents); Virtual Radiologic Corp v Tandem (patent and trade secret claims resulting in injunctions); Purdue Pharma LP v Collegium Pharmaceutical Inc (Hatch-Waxman patent infringement dismissal); Personal Audio LLC v Apple Inc ($8 million jury verdict); Medicis Pharmaceutical Corporation v Upsher-Smith Laboratories (injunction claims defeated); St Clair Intellectual Property Consultants, Inc v Canon, Inc ($34.7 million jury verdict); and St Clair Intellectual Property Consultants, Inc v Sony Corp ($25 million jury verdict).
Mr Holdreith has been named General Patent Litigator of the Year by LMG Life Sciences (2015), an IP Star by Managing Intellectual Property (2015) and a top-listed Lawyer of the Year for IP Litigation by Best Lawyers (2012). He was lead trial counsel in Purdue Pharm v Actavis Elizabeth LLC in the District of New Jersey, selected as Hatch-Waxman Case of the Year by LMG Life Sciences.
*Past results are reported to provide the reader with an indication of the type of litigation in which we practise and do not and should not be construed to create an expectation of result in any other case as all cases are dependent upon their own unique fact situation and applicable law.
Robins Kaplan LLP
800 LaSalle Avenue
Minneapolis MN 55402
Using regression models to isolate the value of a patented feature
Regression models not only can provide a quantitative measure for damages in US patent cases, but also can provide additional insight into topics such as non-infringing alternatives, market equilibriums and cannibalisation that can help to strengthen a damages model
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email